Company News: Page (1) of 1 - 12/12/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

INNATE PHARMA : UPCOMING INVESTOR CONFERENCES

(December 12, 2017)

upcoming investor conferences

  

Marseille, France, December 12, 2017, 7:00 AM CET

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present at the following investor events during the first quarter of 2018:



-      J.P. Morgan Annual Healthcare Conference - San Francisco, January 8-10, 2018

-      Oddo BHF Forum - Lyon, January 11-12, 2018

-      Innate Pharma R&D Day - London, March 8, 2018

*****

The Company will host an

R&D Day on March 8th, 2018,

in London, UK, from 1:00 to 5:00 pm GMT.

Innate Pharma's management team will highlight Innate's leading scientific role in immuno-oncology and its emerging proprietary portfolio, provide a more in-depth look at lead projects, IPH4102 and IPH5401, and their commercial potential.

The event is intended for institutional investors and sell-side analysts only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact Consilium Strategic Communications, at [email protected].

*****

Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section (http://www.innate-pharma.com/en/investors ).

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immunity.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.

The Company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company.

Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code
Ticker code
LEI
FR0010331421
IPH
9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

 

Innate Pharma 

Dr Markus Metzger / Jérôme Marino
Investor relations

Tel.: +33 (0)4 30 30 30 30

[email protected]

 
International Media

 

Consilium Strategic Communications

Mary-Jane Elliott /
Jessica Hodgson

Tel.: +44 (0)20 3709 5700

[email protected]
   

French Media

 

ATCG Press

Marie Puvieux

Mob: +33 (0)6 10 54 36 72

[email protected]

 
Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/0acedbd3-a647-4259-afe1-20f06a905adf


Page: 1


Related Keywords:

[ServletException in:/common/ads/links.jsp] The absolute uri: http://java.sun.com/jstl/core cannot be resolved in either web.xml or the jar files deployed with this application'

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved